Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$23.34 USD

23.34
2,847,490

-0.15 (-0.64%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $23.33 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

CONMED (CNMD) Stock Hits 52-Week High: Will It Continue?

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism in investors due to its broad product spectrum.

Masimo (MASI) Inks Deals for Patient Monitoring Technologies

by Zacks Equity Research

Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.

NextGen (NXGN) Expands Partnership With Large Urology Group

by Zacks Equity Research

NextGen's (NXGN) cloud-based healthcare technology solution, Enterprise EHR, is selected by Associated Urologists of North Carolina to create an integrated platform, especially for urology-specific workflows.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Cooper Companies (COO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.

Here's Why Dentsply (XRAY) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Dentsply (XRAY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Down -7.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Dentsply (XRAY)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Dentsply (XRAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

XRAY vs. COO: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

XRAY vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.

Compared to Estimates, Dentsply (XRAY) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.

West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 18.56% and 2.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q4 earnings and revenues decline year over year due to unfavorable foreign currency movement and soft demand across all geographical segments.

What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.

Why Is Dentsply (XRAY) Up 1% Since Last Earnings Report?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.

What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.

Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.